DELVE BLOG

The COVID-19 pandemic has been an expensive experience, costing months of delay to over 70% of all clinical trials. In the world of clinical research, the pandemic has taught us more about what direct-to-patient trials really means, and how we can innovate to deliver better studies. Interviewing a mix of study sponsors, coordinators and investigators, it is clear that decentralized trials have been proven to deliver faster, easier and cost effective trials. 61% say decentralized trials are faster than traditional trials in, saving clients under 3 months to recruit for a study 75% say decentralized trials are better for patient

Clinical Trials come in multiple flavors, including virtual, hybrid, and fully site-based trials. The impact of COVID-19 on the industry of clinical research and drug delivery has interrupted nearly 80% of the studies, which challenged the ability to conduct trials safely.This has led the industry to think of innovative ways to conduct clinical trials, including the ability for patients to conduct a clinical trial from the comfort of their home. Decentralized Trials has gained enormous momentum to help keep clinical trials moving forward, but what does that mean?Prior to COVID-19, most clinical trials happened at a doctor’s office, including the

W E LCO M E TO T H E D E LV E B LO G . FPO Considering a wearable for an upcoming study? Below are items we often discuss with clients when selecting a device for their study: Study objectives (therapeutic area, the concept of interest, endpoint required, duration of the study, blinded/unblinded data, etc.) Patient centricity (ease of use, passive monitoring or active assessment, reduce the patient burden and support – patient concierge) Device characteristics (scientific evidence and validations, battery life, connectivity) Data (transfer, storage, analytics) Regulatory considerations Privacy and security How else can Delve Health help you? 1.